Expression of mir-143 in serum of bladder cancer patients and its correlation with clinical features and prognosis.
To explore the expression of mir-143 in the serum of bladder cancer patients and its correlation with clinical pathological features and prognosis. A retrospective study was performed on 68 patients (observation group) diagnosed with bladder cancer and treated in the Qilu Hospital of Shandong University from June 2013 to January 2014 and another 40 healthy individuals (control group) in the physical examination center at the same period. Real-time PCR (RT-PCR) was used to detect the expression levels of mir-143 in the serum of bladder cancer patients and healthy subjects. The expression of mir-143 in the serum of bladder cancer patients and its correlation with clinical pathological indicators and prognosis were explored. The expression level of mir-143 in the serum of bladder cancer patients was significantly lower than that of healthy people (p<0.05). There was no statistically significant difference in age and sex (p>0.05). There was a correlation between the expression level of mir-143 and differentiation grade, lymph node metastasis, distant metastasis and clinical stage (p<0.05). The median expression level of mir-143 in the serum of bladder cancer patients was 0.652. Thirty four patients with lower expression than the median of mir-143 were in the low expression group, and 34 patients with higher expression than the median of mir-143 were in the high expression group. The mean survival time of bladder cancer patients with the low expression of mir-143 was 37.32±1.26 months, significantly lower than that with the high expression of mir-143 (46.17±1.54;p<0.05). mir-143 is lowly expressed in the serum of bladder cancer patients. Its expression level is correlated with clinical stage, lymph node metastasis, distant metastasis and prognosis.